Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Post

Showing results (461-470 of 535) with videos related to

Pageof 54
Sort By:
Antiviral Therapy|June 20, 2017
The association between detected drug resistance mutations and CD4<sup>+</sup> T-cell decline in HIV-positive individuals maintained on a failing treatment regimenAnna Schultze, Roger Paredes, Caroline Sabin, et al.
Journal of Clinical and Translational Science|September 22, 2025
Community engagement strategies improve recruitment and enrollment in a pragmatic clinical trialKari G Vance, Jonah Pedelty, Barbara J Van Gorp, et al.
JIMD Reports|May 13, 2024
Oral ribose supplementation in dystroglycanopathy: A single case studyR M J Thewissen, M A Post, D M Maas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 8, 2018
Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY TrialFrank A Post, Alexander J Szubert, Andrew J Prendergast, et al.
HIV Medicine|January 29, 2026
Screening for Trypanosoma cruzi infection (Chagas disease) in the Latin American population living with HIV in LondonNatalie Elkheir, Shivani Singh, Birgit Barbini, et al.
The Lancet. HIV|March 6, 2017
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyEdwin DeJesus, Moti Ramgopal, Gordon Crofoot, et al.
JAMA|July 24, 2012
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trialNicholas I Paton, Ruth L Goodall, David T Dunn, et al.
European Journal of Pain (London, England)|March 12, 2021
Feasibility randomized-controlled trial of online acceptance and commitment therapy for painful peripheral neuropathy in people living with HIV: The OPEN studyWhitney Scott, Beth J Guildford, James Badenoch, et al.
The Lancet. Infectious Diseases|January 19, 2019
Clinical utility of existing and second-generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort studyHilary S Whitworth, Amarjit Badhan, Aime A Boakye, et al.
Cells|November 26, 2022
The Predicted Splicing Variant c.11+5G>A in <i>RPE65</i> Leads to a Reduction in mRNA Expression in a Cell-Specific MannerIrene Vázquez-Domínguez, Lonneke Duijkers, Zeinab Fadaie, et al.
Pageof 54

Showing results (461-470 of 535) with videos related to

Sort By:
Pageof 54
Antiviral Therapy|June 20, 2017
The association between detected drug resistance mutations and CD4<sup>+</sup> T-cell decline in HIV-positive individuals maintained on a failing treatment regimenAnna Schultze, Roger Paredes, Caroline Sabin, et al.
Journal of Clinical and Translational Science|September 22, 2025
Community engagement strategies improve recruitment and enrollment in a pragmatic clinical trialKari G Vance, Jonah Pedelty, Barbara J Van Gorp, et al.
JIMD Reports|May 13, 2024
Oral ribose supplementation in dystroglycanopathy: A single case studyR M J Thewissen, M A Post, D M Maas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 8, 2018
Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY TrialFrank A Post, Alexander J Szubert, Andrew J Prendergast, et al.
HIV Medicine|January 29, 2026
Screening for Trypanosoma cruzi infection (Chagas disease) in the Latin American population living with HIV in LondonNatalie Elkheir, Shivani Singh, Birgit Barbini, et al.
The Lancet. HIV|March 6, 2017
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyEdwin DeJesus, Moti Ramgopal, Gordon Crofoot, et al.
JAMA|July 24, 2012
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trialNicholas I Paton, Ruth L Goodall, David T Dunn, et al.
European Journal of Pain (London, England)|March 12, 2021
Feasibility randomized-controlled trial of online acceptance and commitment therapy for painful peripheral neuropathy in people living with HIV: The OPEN studyWhitney Scott, Beth J Guildford, James Badenoch, et al.
The Lancet. Infectious Diseases|January 19, 2019
Clinical utility of existing and second-generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort studyHilary S Whitworth, Amarjit Badhan, Aime A Boakye, et al.
Cells|November 26, 2022
The Predicted Splicing Variant c.11+5G>A in <i>RPE65</i> Leads to a Reduction in mRNA Expression in a Cell-Specific MannerIrene Vázquez-Domínguez, Lonneke Duijkers, Zeinab Fadaie, et al.
Pageof 54